Dr Reddy's Launches Depression Treatment Drug in US
Drug maker Dr Reddy's Laboratories on Friday said it has launched duloxetine delayed-release capsules in strengths 20 mg (USP), 30 mg and 60 mg in the US market.
According to IMS health, Cymbalta (duloxetine delayed- release capsules) brand and generic had US sales of $5.04 billion for the most recent 12 months ending April 2014, Dr Reddy's said in the statement.
The US Food and Drug Administration (FDA) in December last year approved the first generic versions of Cymbalta (duloxetine delayed-release capsules) for Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharma Global FZE, Teva Pharmaceuticals USA and Torrent Pharmaceuticals Ltd to market the drug in various strengths.
Cymbalta (duloxetine) is used to treat major depressive disorder, general anxiety disorder and fibromyalgia. Common adverse reactions reported by people taking Cymbalta include nausea, dry mouth, drowsiness, fatigue, decreased appetite, increased sweating, and dizziness, the US drug regulator had said on its website earlier.
Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs.
Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs, it had said
As of 12:53 p.m., shares in Dr Reddy's Laboratories Ltd were trading at Rs 2541.30 apiece on the BSE, up 1.46 per cent from the previous close.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
